Drug Type Monoclonal antibody |
Synonyms ogalvibart |
Target |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | AR | 19 Aug 2020 | |
COVID-19 | Phase 3 | AR | 19 Aug 2020 | |
COVID-19 | Phase 3 | US | 19 Aug 2020 | |
COVID-19 | Phase 3 | US | 19 Aug 2020 | |
COVID-19 | Phase 3 | GT | 19 Aug 2020 | |
COVID-19 | Phase 3 | BR | 19 Aug 2020 | |
COVID-19 | Phase 3 | MX | 19 Aug 2020 | |
COVID-19 | Phase 3 | BR | 19 Aug 2020 | |
COVID-19 | Phase 3 | PR | 19 Aug 2020 | |
COVID-19 | Phase 3 | US | 19 Aug 2020 |